Natural compounds as non-nucleoside inhibitors of Zika virus polymerase through integration of in silico and in vitro approaches

dc.creatorRamos, Paulo Ricardo Pimenta da Silva
dc.creatorMottin, Melina
dc.creatorLima, Caroline Sprengel
dc.creatorAssis, Leticia Ribeiro de
dc.creatorOliveira, Ketllyn Zagato de
dc.creatorMesquita, Nathalya Cristina de Moraes Roso
dc.creatorCassani, Natasha Marques
dc.creatorSantos, Igor de Andrade
dc.creatorBorba, Joyce Villa Verde Bastos
dc.creatorCosta, Vinícius Alexandre Fiaia
dc.creatorNeves, Bruno Junior
dc.date.accessioned2024-09-12T15:24:25Z
dc.date.available2024-09-12T15:24:25Z
dc.date.issued2022
dc.description.abstractAlthough the past epidemic of Zika virus (ZIKV) resulted in severe neurological conse quences for infected infants and adults, there are still no approved drugs to treat ZIKV infection. In this study, we applied computational approaches to screen an in-house database of 77 natural and semi-synthetic compounds against ZIKV NS5 RNA-dependent RNA-polymerase (NS5 RdRp), an essential protein for viral RNA elongation during the replication process. For this purpose, we integrated computational approaches such as binding-site conservation, chemical space analysis and molecular docking. As a result, we prioritized nine virtual hits for experimental evaluation. Enzymatic assays confirmed that pedalitin and quercetin inhibited ZIKV NS5 RdRp with IC50 values of 4.1 and 0.5 µM, respectively. Moreover, pedalitin also displayed antiviral activity on ZIKV infection with an EC50 of 19.28 µM cell-based assays, with low toxicity in Vero cells (CC50 = 83.66 µM) and selectivity index of 4.34. These results demonstrate the potential of the natural compounds pedal itin and quercetin as candidates for structural optimization studies towards the discovery of new anti-ZIKV drug candidates.
dc.identifier.citationRAMOS, Paulo Ricardo Pimenta da Silva et al. Natural compounds as non-nucleoside inhibitors of Zika virus polymerase through integration of in silico and in vitro approaches. Pharmaceuticals, Basel, v. 15, n. 12, p. 1493, 2022. DOI: 10.3390/ph15121493. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788182/. Acesso em: 5 set. 2024.
dc.identifier.doi10.3390/ph15121493
dc.identifier.issn1424-8247
dc.identifier.urihttp://repositorio.bc.ufg.br//handle/ri/25514
dc.language.isoeng
dc.publisher.countrySuica
dc.publisher.departmentFaculdade de Farmácia - FF (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectZika virus
dc.subjectAntiviral
dc.subjectPolymerase
dc.subjectDocking
dc.subjectNS5 RdRp protein
dc.subjectDrug discovery
dc.subjectFlavonoid
dc.subjectPedalitin
dc.subjectQuercetin
dc.subjectNon-nucleoside inhibitor
dc.titleNatural compounds as non-nucleoside inhibitors of Zika virus polymerase through integration of in silico and in vitro approaches
dc.typeArtigo

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
Artigo - Paulo Ricardo Pimenta da Silva Ramos - 2022.pdf
Tamanho:
3.19 MB
Formato:
Adobe Portable Document Format

Licença do Pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: